Considering some data indicates parts of Europe has a much higher rate Dupuytrens this isn't good news for sales. Since they got Actelion as a partner in Canada I imagine they are the likely one to pick up Europe. I wonder if Pfizer didn't see the potential or didn't like the data for Peyronie's.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.